Skip to content
National Association of Attorneys General
  • For Members
    • How Do I…?
    • Member Benefits
    • Scholarships & Nominations
    • Specialized Services
    • Committees
    • Office Support
    • Member Directory
    • Account & Access
  • Events & Training
    • Event Calendar
    • Upcoming Programs
    • Training Opportunities
    • On-Demand Resources
    • CLE Credit
    • Mobile Training Requests
    • Our Faculty
  • Resources
    • Policy Letters
    • Reports & Publications
    • Research & Data
    • Attorney General Journal
    • Newsroom
    • Databases & Tools
    • Public Resources
  • Attorney Generals
    • What Attorneys General Do
    • Attorneys General Office 101
    • Find my AG
    • How AGs Are Selected
    • Issues Attorney Generals Work On
    • Consumer Complaint Guidance
    • Attorney General Elections
    • Past Attorneys General
    • Careers in Attorney General Offices
  • NAMFCU
    • History of NAMFCU
    • About NAMFCU
    • NAMFCU
    • About the Medicaid Fraud Control Units
    • NAMFCU Trainings
    • MFCU Member Hub
    • Reporting Fraud and Abuse
    • Careers with a MFCU
  • About
    • About Us
    • NAAG History
    • Leadership
    • Staff
    • Regions
    • Careers at NAAG
    • FAQs
    • SAGE
    • Contact Us
  • Log In
PUBLIC RESOURCES           NEWSROOM           CONTACT US
Log In
National Association of Attorneys General
  • For Members
    • How Do I…?
    • Member Benefits
    • Scholarships & Nominations
    • Specialized Services
    • Committees
    • Office Support
    • Member Directory
    • Account & Access
  • Events & Training
    • Event Calendar
    • Upcoming Programs
    • Training Opportunities
    • On-Demand Resources
    • CLE Credit
    • Mobile Training Requests
    • Our Faculty
  • Resources
    • Policy Letters
    • Reports & Publications
    • Research & Data
    • Attorney General Journal
    • Newsroom
    • Databases & Tools
    • Public Resources
  • Attorney Generals
    • What Attorneys General Do
    • Attorneys General Office 101
    • Find my AG
    • How AGs Are Selected
    • Issues Attorney Generals Work On
    • Consumer Complaint Guidance
    • Attorney General Elections
    • Past Attorneys General
    • Careers in Attorney General Offices
  • NAMFCU
    • History of NAMFCU
    • About NAMFCU
    • NAMFCU
    • About the Medicaid Fraud Control Units
    • NAMFCU Trainings
    • MFCU Member Hub
    • Reporting Fraud and Abuse
    • Careers with a MFCU
  • About
    • About Us
    • NAAG History
    • Leadership
    • Staff
    • Regions
    • Careers at NAAG
    • FAQs
    • SAGE
    • Contact Us
  • Log In

Attorneys General Call on Congress to Pass the Combating Illicit Xylazine Act

Home / NAAG, Attorneys General / Attorneys General Call on Congress to Pass the Combating Illicit Xylazine Act
May 18, 2023 NAAG, Attorneys General
Share this

Washington, D.C. – The National Association of Attorneys General (NAAG) today sent a letter on behalf of a bipartisan group of 39 state and territory attorneys general calling on Congressional leadership to pass the Combating Illicit Xylazine Act (H.R.1839/S.993). This Act would provide critical measures to combat the widespread illicit use and trafficking of xylazine and help prevent xylazine-related deaths.

The letter from the attorneys general follows a surge in overdose deaths nationwide related to xylazine, a potent veterinary medication that has been widely mixed with opioids like fentanyl and is easily obtainable online. Over the past few months, multiple federal agencies, including the U.S. Drug Enforcement Administration (DEA), have issued public alerts about the dangers of xylazine. The White House recently declared fentanyl-adulterated or -associated xylazine (FAAX) an “emerging threat” to the nation.

“Xylazine is a growing danger to communities across our nation. With a record number of overdose deaths, we must confront this new threat,” wrote the attorneys general in the letter. “We agree that Congress must act quickly to classify the illicit use of xylazine under Schedule III of the Controlled Substances Act (CSA). The Combating Illicit Xylazine Act provides critical tools that will enable the DEA to track its manufacturing, prevent diversion, and mandate analysis and reporting on the illicit use of xylazine.”

Xylazine is only approved by the U.S. Food and Drug Administration (FDA) as a veterinary medicine used to sedate and relieve pain in large animals. In humans, xylazine is known to depress breathing and heart rate, lower blood pressure, and cause unconsciousness, necrosis, and even death. Xylazine is not an opioid, thus existing medications like naloxone are not effective in reversing the drug’s effects even if used with opioids.

According to the DEA, there was a dramatic increase in xylazine-related overdose deaths across the United States between 2020 and 2021. Additionally, in 2022, approximately 23 percent of fentanyl powder and seven percent of fentanyl pills seized by the DEA contained xylazine. To prevent the proliferation of FAAX in communities and keep people safe, the bipartisan coalition of attorneys general urge Congress to pass the important measures outlined in the Combating Illicit Xylazine Act.

Attorneys general from the following states and territories signed the letter: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Nevada, New Hampshire, New Mexico, New York, North Carolina, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

# # #

The National Association of Attorneys General (NAAG) is the nonpartisan national forum for America’s state and territory attorneys general and their staff. NAAG provides a community for members to collaboratively address issues important to their work and resources to support attorneys general in protecting the rule of law and the United States Constitution.

Media Contact

media@naag.org

Sign-up to receive NAAG’s monthly newsletter.

Latest News

  • Bipartisan Coalition of 45 Attorneys General Backs Pharmacy Benefit Manager (PBM) Transparency Rule April 17, 2026
  • Supreme Court Report, Volume 33, Issue 10 April 8, 2026
  • Supreme Court Report, Volume 33, Issue 9 April 1, 2026
  • Bipartisan Coalition of Attorneys General Urges Congress to Pass Legislation Against Illicit Xylazine March 31, 2026
  • Supreme Court Report, Volume 33, Issue 8 March 23, 2026

Recent Posts

  • Bipartisan Coalition of 45 Attorneys General Backs Pharmacy Benefit Manager (PBM) Transparency Rule
  • Supreme Court Report, Volume 33, Issue 10
  • Supreme Court Report, Volume 33, Issue 9
  • Bipartisan Coalition of Attorneys General Urges Congress to Pass Legislation Against Illicit Xylazine
  • Supreme Court Report, Volume 33, Issue 8

Stay Connected

Get NAAG updates and training alerts.

Create an account and then select your preferred mailings (otherwise, we will send you everything).

Create Account
Set Marketing Preferences
Log In to Your Account
White Logo for the National Association of Attorneys General

1850 M Street NW, Suite 1200
Washington, DC  20036
Telephone: (202) 326-6000
support@naag.org

Our Work

  • Bankruptcy
  • Consumer Protection
  • Tobacco and Public Health
  • Center for Supreme Court Advocacy

Resources

  • Attorney General Journal
  • CLE Policy and Guidelines
  • Event Calendar
  • NAAG Policy Letters
  • Reports & Publications

ABOUT

  • Leadership
  • Staff
  • NAAG History
  • Mission Foundation
  • Careers at NAAG
  • Contact Us

© 2026 Copyright National Association of Attorneys General

Website by Yoko Co

Internal Feedback / Report an Error

Request an Update / Report an Error

The change you are requesting will be linked to this page. The URL for the page will be included in a hidden field when the form is submitted.
Please enter your change or describe your request. Be sure to reference where the error appears on the page and what needs to be done specifically.
Upload any files that need to be linked to this page. PDF only. Submit another request if you have more than five files to upload.
Drop files here or
Accepted file types: pdf, docx, xls, Max. file size: 128 MB, Max. files: 5.

    Who is requesting this change?(Required)
    Scroll To Top

    Insert/edit link

    Enter the destination URL

    Or link to existing content

      No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.
        This site is registered on Toolset.com as a development site.
        To provide you more clarity about how we collect, store and use personal information, and your rights to control that information, we have updated our privacy policy, which also explains how we use cookies. You consent to our cookies if you continue to use our website.